Expanding on this idea, we tested the efficacy of type 1 IFN inhibition in a mouse model of CAV and demonstrated that inhibition of IFN signaling drastically reduced the incidence of vasculopathy in treated recipients and significantly prolonged allograft survival. Here, IFNA1 is linked to vascular disorder.